Notice of Closed Meeting, 75019-75020 [2020-25960]

Download as PDF Federal Register / Vol. 85, No. 227 / Tuesday, November 24, 2020 / Notices J (see ‘‘General Routine Uses of Board Systems of Records available at https:// www.federalreserve.gov/files/SORNpage-general-routine-uses-of-boardsystems-of-records.pdf). The BGFRS–24 SORN provides that the information may be disclosed outside the Board in accordance with general routine uses A, B, C, D, E, F, G, I, and J (see id.). The BGFRS–1 SORN also provides that all or part of the record may be disclosed outside of the Board in order to disclose information to any source from which additional information is requested (to the extent necessary to identify the individual, inform the source of the purpose(s) of the request, and identify the type of information requested), when necessary to obtain information relevant to a Board decision to hire or retain an employee, issue a security clearance, conduct a security or suitability investigation of an individual, classify jobs, let a contract, or issue a license, grant or other benefit. Correction In the Federal Register of September 30, 2020, in FR Doc 2020–21604, on page 61752, in the first column, correct the ‘‘Date’’ and ‘‘Time’’ captions to read: Date: January 12, 2021. Time: 10:00 a.m.–6:00 p.m., EST. The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. [FR Doc. 2020–25959 Filed 11–23–20; 8:45 am] DEPARTMENT OF HEALTH AND HUMAN SERVICES BILLING CODE 4163–18–P [FR Doc. 2020–25885 Filed 11–23–20; 8:45 am] Centers for Disease Control and Prevention Notice of Closed Meeting Centers for Disease Control and Prevention Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—DD21–001, Study To Explore Early Development (SEED) Follow Up Studies; Correction Centers for Disease Control and Prevention (CDC), Health and Human Services. ACTION: Notice; correction. AGENCY: The CDC published a document in the Federal Register of September 30, 2020, concerning a closed meeting of the Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)— DD21–001, Study to Explore Early Development (SEED) Follow up Studies. The document contained incorrect dates. jbell on DSKJLSW7X2PROD with NOTICES SUMMARY: Jaya Raman Ph.D., Scientific Review Officer, CDC, 4770 Buford Highway, Mailstop S107–8, Atlanta, Georgia 30341, Telephone: (770) 488–6511, JRaman@ cdc.gov. FOR FURTHER INFORMATION CONTACT: SUPPLEMENTARY INFORMATION: VerDate Sep<11>2014 17:48 Nov 23, 2020 Jkt 253001 Kalwant Smagh, Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention. [FR Doc. 2020–25961 Filed 11–23–20; 8:45 am] DEPARTMENT OF HEALTH AND HUMAN SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES Willowdale Road, Morgantown, WV 26506, Telephone: (304) 285–5951, MGoldcamp@cdc.gov. The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Kalwant Smagh, Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention. Board of Governors of the Federal Reserve System, November 18, 2020. Michele Taylor Fennell, Deputy Associate Secretary of the Board. BILLING CODE 6210–01–P 75019 Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, CDC, pursuant to Public Law 92–463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)–PAR 18–812, NIOSH Member Conflict Review. Date: February 22, 2021. Time: 1:00 p.m.–5:00 p.m., EST. Place: Teleconference. Agenda: To review and evaluate grant applications. FOR FURTHER INFORMATION CONTACT: Michael Goldcamp, Ph.D., Scientific Reviewer Officer, Office of Extramural Programs, CDC/NIOSH, 1095 PO 00000 Frm 00048 Fmt 4703 Sfmt 4703 BILLING CODE 4163–18–P Centers for Disease Control and Prevention Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, CDC, pursuant to Public Law 92–463. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)– DD21–002, Characterizing the Natural History of Fragile X Syndrome to Inform the Development of Intervention Outcome Measures. Date: March 23, 2021. Time: 10:00 a.m.–6:00 p.m., EST. Place: Teleconference. Agenda: To review and evaluate grant applications. FOR FURTHER INFORMATION CONTACT: Jaya Raman Ph.D., Scientific Review Officer, CDC, 4770 Buford Highway, Mailstop S107–8, Atlanta, Georgia 30341, E:\FR\FM\24NON1.SGM 24NON1 75020 Federal Register / Vol. 85, No. 227 / Tuesday, November 24, 2020 / Notices Telephone: (770) 488–6511, JRaman@ cdc.gov. The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Prevention and the Agency for Toxic Substances and Disease Registry. Kalwant Smagh, Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention. [FR Doc. 2020–25960 Filed 11–23–20; 8:45 am] BILLING CODE 4163–18–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Administration for Children and Families Proposed Information Collection Activity; Generic Clearance for the Collection of Qualitative Feedback on Agency Service Delivery (OMB #0970– 0401) Administration for Children and Families, HHS. ACTION: Request for Public Comment. AGENCY: The Administration for Children and Families (ACF) proposes to extend data collection under the existing overarching Generic Clearance for the Collection of Qualitative Feedback on Agency Service Delivery (OMB #0970–0401). There are no changes to the proposed types of SUMMARY: information collection or uses of data, but ACF is requesting an increase to the estimated number of respondents. DATES: Comments due within 60 days of publication. In compliance with the requirements of Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, ACF is soliciting public comment on the specific aspects of the information collection described above. ADDRESSES: Copies of the proposed collection of information can be obtained and comments may be forwarded by emailing infocollection@ acf.hhs.gov. Alternatively, copies can also be obtained by writing to the Administration for Children and Families, Office of Planning, Research, and Evaluation (OPRE), 330 C Street SW, Washington, DC 20201, Attn: ACF Reports Clearance Officer. All requests, emailed or written, should be identified by the title of the information collection. SUPPLEMENTARY INFORMATION: Description: Executive Order 12862 directs federal agencies to provide service to the public that matches or exceeds the best service available in the private sector. As outlined in Memorandum M–11–26, the Office of Management and Budget (OMB) worked with agencies to create a Fast Track Process to allow agencies to obtain timely feedback on service delivery while ensuring that the information collected is useful and minimally burdensome for the public, as required by the Paperwork Reduction Act of 1995. ACF created this generic clearance in response to this effort by OMB. In order to work continuously to ensure that the ACF programs are effective and meet our customers’ needs, we use this Fast Track generic clearance Instrument jbell on DSKJLSW7X2PROD with NOTICES Example instruments include: Customer Comment Card/Complaint Form ............................................ Customer Satisfaction Survey Usability Testing (e.g., Website or Software) Small Discussion Group Focus Group Estimated Total Annual Burden Hours: 12,500. Comments: The Department specifically requests comments on (a) whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency’s estimate of the burden of the proposed collection of information; (c) the quality, utility, VerDate Sep<11>2014 17:48 Nov 23, 2020 Jkt 253001 Frm 00049 Fmt 4703 Annual Burden Estimates Based on the use of this generic clearance over the past 3 years, ACF is requesting an increase to the estimated number of respondents from 10,000 to 12,500. Total number of respondents Total number of responses per respondent Average burden hours per response Total burden hours 12,500 1 .5 6,250 and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology. Consideration will be given to comments and suggestions submitted within 60 days of this publication. PO 00000 process to collect qualitative feedback on our service delivery. This collection of information is necessary to enable ACF to garner customer and stakeholder feedback in an efficient, timely manner in accord with our commitment to improving service delivery. The information collected from our customers and stakeholders helps ensure that users have an effective, efficient, and satisfying experience with the programs. This feedback provides insights into customer or stakeholder perceptions, experiences, and expectations; provides an early warning of issues with service; or focus attention on areas where communication, training, or changes in operations might improve delivery of products or services. These collections allow for ongoing, collaborative, and actionable communications between ACF and its customers and stakeholders. They also allow feedback to contribute directly to the improvement of program management. Per Memorandum M–11–26, information collection requests submitted under this Fast Track generic will be considered approved unless OMB notifies ACF otherwise within 5 days. Respondents: ACF program participants, potential program participants, stakeholders, and other customers. Sfmt 9990 Authority: Social Security Act, Sec. 1110. [42 U.S.C. 1310]. Mary B. Jones, ACF/OPRE Certifying Officer. [FR Doc. 2020–25978 Filed 11–23–20; 8:45 am] BILLING CODE 4184–79–P E:\FR\FM\24NON1.SGM 24NON1

Agencies

[Federal Register Volume 85, Number 227 (Tuesday, November 24, 2020)]
[Notices]
[Pages 75019-75020]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2020-25960]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention


Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended, and the Determination of the Director, Strategic 
Business Initiatives Unit, Office of the Chief Operating Officer, CDC, 
pursuant to Public Law 92-463. The grant applications and the 
discussions could disclose confidential trade secrets or commercial 
property such as patentable material, and personal information 
concerning individuals associated with the grant applications, the 
disclosure of which would constitute a clearly unwarranted invasion of 
personal privacy.
    Name of Committee: Disease, Disability, and Injury Prevention and 
Control Special Emphasis Panel (SEP)-DD21-002, Characterizing the 
Natural History of Fragile X Syndrome to Inform the Development of 
Intervention Outcome Measures.
    Date: March 23, 2021.
    Time: 10:00 a.m.-6:00 p.m., EST.
    Place: Teleconference.
    Agenda: To review and evaluate grant applications.

FOR FURTHER INFORMATION CONTACT:  Jaya Raman Ph.D., Scientific Review 
Officer, CDC, 4770 Buford Highway, Mailstop S107-8, Atlanta, Georgia 
30341,

[[Page 75020]]

Telephone: (770) 488-6511, [email protected].
    The Director, Strategic Business Initiatives Unit, Office of the 
Chief Operating Officer, Centers for Disease Control and Prevention, 
has been delegated the authority to sign Federal Register notices 
pertaining to announcements of meetings and other committee management 
activities, for both the Centers for Disease Control and Prevention and 
the Agency for Toxic Substances and Disease Registry.

Kalwant Smagh,
Director, Strategic Business Initiatives Unit, Office of the Chief 
Operating Officer, Centers for Disease Control and Prevention.
[FR Doc. 2020-25960 Filed 11-23-20; 8:45 am]
BILLING CODE 4163-18-P